Thus, the TLR3/4-TBK1-IRF3-IL-33 signaling pathway activation by HBV plus carcinogen is a mechanism that explains hepatitis and HCC risk associated with HBV infection, which can be blocked by statin to suppress hepatitis and HCC. This evidence concerns the gene TLR3 and hepatocellular carcinoma.